Press Releases Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:42 24/06/2025 BST			5-day change	1st Jan Change
262.10 ^CHF	+0.61%		+0.19%	+2.58%

06-23	Roche Holding AG - Special Call
06-23	Lineage Cell Therapeutics, Inc. Announces 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025	CI

Press Releases

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma	06-20	BU
Genentech Provides Update on Phase III Verona Study	06-16	BU
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease	06-16	BU
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer	06-02	BU
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer	05-31	BU
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis	05-30	BU
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients	05-23	BU
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy	05-22	BU
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	05-20	BU
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer	05-13	BU
Roche and Genentech Announce New North Carolina Manufacturing Facility	05-12	BU
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission	04-25	BU
Roche : Q1 2025 Presentation with appendix (irp250424)	04-24	PU
Roche : Q1 2025 Presentation (irp250424 a)	04-24	PU
Swiss pharma giant Roche to invest $50 billion in US, creating 12,000 jobs	04-22	AQ
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025	04-03	BU
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis	04-02	BU
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis	03-05	BU
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults	03-03	BU
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies	03-02	BU
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)	02-12	BU
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis	02-07	BU
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis	02-07	AQ
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness	02-04	BU
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU	01-31	AQ